ATE55151T1 - Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen. - Google Patents

Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.

Info

Publication number
ATE55151T1
ATE55151T1 AT84300091T AT84300091T ATE55151T1 AT E55151 T1 ATE55151 T1 AT E55151T1 AT 84300091 T AT84300091 T AT 84300091T AT 84300091 T AT84300091 T AT 84300091T AT E55151 T1 ATE55151 T1 AT E55151T1
Authority
AT
Austria
Prior art keywords
yeast
synthesis
expression systems
foreign proteins
containing vectors
Prior art date
Application number
AT84300091T
Other languages
English (en)
Inventor
Rae Lyn Burke
Olson Patricia Tekamp
Steven Rosenberg
Pablo D T Valenzuela
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23860419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE55151(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE55151T1 publication Critical patent/ATE55151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Toys (AREA)
AT84300091T 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen. ATE55151T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46858983A 1983-02-22 1983-02-22
EP84300091A EP0120551B1 (de) 1983-02-22 1984-01-06 Expressionssysteme für Hefe mit einen GAPDH Promotor enthaltenden Vektoren und Synthese von Fremdproteinen

Publications (1)

Publication Number Publication Date
ATE55151T1 true ATE55151T1 (de) 1990-08-15

Family

ID=23860419

Family Applications (3)

Application Number Title Priority Date Filing Date
AT84300091T ATE55151T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.
AT91114001T ATE138975T1 (de) 1983-02-22 1984-01-06 Expressionssysteme für hefe mit vektoren, die einen gapdh-promotor enthalten und oberflächenantigensynthese von hepatitis b
AT89106868T ATE93894T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT91114001T ATE138975T1 (de) 1983-02-22 1984-01-06 Expressionssysteme für hefe mit vektoren, die einen gapdh-promotor enthalten und oberflächenantigensynthese von hepatitis b
AT89106868T ATE93894T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.

Country Status (7)

Country Link
EP (4) EP0732403A1 (de)
JP (2) JPS59210888A (de)
AT (3) ATE55151T1 (de)
CA (2) CA1341302C (de)
DE (3) DE3486206T2 (de)
DK (1) DK173604B1 (de)
SG (1) SG48422A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPS5936699A (ja) * 1982-08-20 1984-02-28 Chemo Sero Therapeut Res Inst シヤトルベクタ−
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
US5422267A (en) * 1984-05-22 1995-06-06 Robert R. Yocum Industrial yeast comprising an integrated glucoamylase gene
EP0173997A1 (de) * 1984-09-06 1986-03-12 Chiron Corporation Katzenleukämievirusproteinimpfstoffe und ihre Herstellung
US5336609A (en) * 1984-12-06 1994-08-09 Labofina, S.A. Transformed yeasts for producing lysozyme, plasmids used for this transformation, method of producing lysozyme
EP0211767B1 (de) * 1985-08-05 1991-03-06 Merck & Co. Inc. Verfahren zur Steigerung der Produktion von rekombinantem Protein in Hefearten der Gattung Saccharomyces
ES2028779T3 (es) * 1985-10-03 1992-07-16 Green Cross Corporation Promotor de levadura y procedimiento para preparar proteina heterologa.
JPH0655155B2 (ja) * 1985-10-03 1994-07-27 株式会社ミドリ十字 蛋白質の製造方法
DK162900C (da) * 1985-10-24 1992-05-11 Danisco Fremgangsmaade til ekspression af gener i gaer samt dna-fragment, rekombineret dna-segment og plasmider, hvor disse indgaar til brug ved udoevelse af fremgangsmaaden
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
JPS62236496A (ja) * 1986-04-07 1987-10-16 Green Cross Corp:The ＨＢｓＡｇの製造方法
US4839283A (en) * 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
JPH02501186A (ja) * 1987-06-22 1990-04-26 メディコ　ラブス　アクチェンゲゼルシャフト 異種ウイルス性ペプチド粒子の免疫原
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
AU644619B2 (en) 1989-12-21 1993-12-16 Advanced Technologies (Cambridge) Limited Modification of plant metabolism
FI103206B1 (fi) * 1990-01-29 1999-05-14 Novartis Ag Uusi ilmentämisjärjestelmä sieniä varten
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
IE914102A1 (en) 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
ATE249838T1 (de) 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
JPH08173170A (ja) * 1994-05-25 1996-07-09 Kirin Brewery Co Ltd キャンディダ・ユティリス酵母の形質転換系、およびそれによる異種遺伝子の発現
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US6329141B1 (en) 1995-12-22 2001-12-11 Dsm N.V. Methods for transforming Phaffia strains, transformed Phaffia strains so obtained and recombinant DNA in said methods
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
ES2333071T5 (es) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
US6087128A (en) 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2275553B1 (de) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Antigenpeptide aus Neisseria
US6709863B2 (en) 1999-12-08 2004-03-23 Iowa State University Research Foundation Nucleic acid molecules encoding multiple start codons and histidine tags
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
AU2002227883A1 (en) 2001-01-25 2002-08-06 Evolva Biotech A/S A library of a collection of cells
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
KR100982204B1 (ko) 2001-12-12 2010-09-14 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 클라미디아 트라코마티스에 대한 면역화
CA2485703A1 (en) 2002-05-24 2003-12-04 Fred W. Wagner Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
SI1704234T1 (sl) 2003-11-21 2012-08-31 Nps Pharma Inc Proizvodnja glukagonu podobnih peptidov 2 in analogov
DE10356218A1 (de) * 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
CA2553035A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
EP1771573A4 (de) 2004-07-21 2009-02-18 Ambrx Inc Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
SG158186A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
EP1871411A4 (de) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic Expression von hepatitis-b-virus-oberflächenantigen für impfstoffherstellung
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
AU2006286228A1 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
CA2882445A1 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
EP2615108B1 (de) 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
WO2008139591A1 (ja) * 2007-05-11 2008-11-20 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 組換えアプロチニンの生産方法
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
HUE035168T2 (en) 2008-09-26 2018-05-02 Ambrx Inc Modified animal erythropoietin polypeptides and their applications
EA201170493A1 (ru) 2008-09-26 2011-10-31 Амбркс, Инк. Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
EP2805965A1 (de) 2009-12-21 2014-11-26 Ambrx, Inc. Modifizierte Schweine-Somatotropin-Polypeptide und deren Verwendungen
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
EP2571991A1 (de) 2010-05-20 2013-03-27 Evolva SA Verfahren zur herstellung von isoprenoidverbindungen in hefe
SI3572091T1 (sl) 2010-08-17 2024-07-31 Ambrx, Inc., Modificirani polipeptidi relaksina in njihova uporaba
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
ATE42338T1 (de) * 1982-05-19 1989-05-15 Unilever Nv Hefe des genus kluyveromyces, modifiziert zur expression von preprothaumatin oder seinen verschiedenen allelischen und modifizierten formen oder maturationsformen.
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPH0716432B2 (ja) * 1982-10-20 1995-03-01 サントリー株式会社 酵母の高発現ベクタープラスミドを用いたペプチドの生産方法

Also Published As

Publication number Publication date
JPH0515431B2 (de) 1993-03-01
DK577783A (da) 1984-08-23
EP0460716A1 (de) 1991-12-11
EP0732403A1 (de) 1996-09-18
JPH05268984A (ja) 1993-10-19
DE3486431T3 (de) 2000-05-04
CA1341302C (en) 2001-10-09
DE3482844D1 (de) 1990-09-06
DE3486206D1 (de) 1993-10-07
ATE138975T1 (de) 1996-06-15
JPH0724594B2 (ja) 1995-03-22
SG48422A1 (en) 1998-04-17
EP0120551B1 (de) 1990-08-01
ATE93894T1 (de) 1993-09-15
CA1341116C (en) 2000-10-17
EP0329203B1 (de) 1993-09-01
DK173604B1 (da) 2001-04-23
DE3486431T2 (de) 1996-10-10
EP0120551A2 (de) 1984-10-03
DE3486431D1 (de) 1996-07-11
EP0120551A3 (en) 1986-05-14
EP0460716B1 (de) 1996-06-05
EP0460716B2 (de) 1999-12-15
DE3486206T2 (de) 1994-02-03
DK577783D0 (da) 1983-12-15
EP0329203A1 (de) 1989-08-23
JPS59210888A (ja) 1984-11-29

Similar Documents

Publication Publication Date Title
ATE55151T1 (de) Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.
EP1245678A3 (de) Rekombinante Proteine von mit Lymphadenopathiesyndrom und/oder erworbenem Immunschwächesyndrom assoziierten Viren
AU6733487A (en) Mammalian interleukin-4
ES2123006T3 (es) Levaduras recombinantes altamente estables para la produccion de proteinas recombinantes.
EP0123544A3 (de) Verfahren zur Expression von heterologen Proteinen in Hefe, Expressionsvektoren und Hefe-Organismen dafür
DE59504181D1 (de) Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
DE68928380D1 (de) Expression von menschlichen Serumalbumin in methylotrophischen Hefen
DK27885A (da) Fremstilling af peptider
DE3485444D1 (de) Hybrid-dns-synthese von insulin.
ES8504254A1 (es) Procedimiento para obtener un polipeptido
ES8602137A1 (es) Procedimiento para obtener una proteina heterologa para levaduras
ES2074046T5 (es) Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano.
DE3850774D1 (de) Rinder-interleukin-1-alpha.
AU7378087A (en) Interleukin-2 induced antineoplastic peptide
FI934079L (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time